US equities |
TSLA $394.62 ▲+6.02% MU $892.03 ▲+1.65% SPCX $148.29 ▲+0.55% NVDA $216.07 ▲+2.42% META $644.00 ▲+0.22% SNDK $1,243.01 ▲+0.40% AAPL $346.24 ▼-0.43% AMZN $250.06 ▲+0.83%
FinancialContent

Abeona Therapeutics Inc. - Common Stock (NQ:ABEO)

4.330 -0.070 (-1.59%)
Delayed Quote Updated: 10:45 AM EDT, Oct 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abeona Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Abeona Therapeutics® Announces Date of First Quarter Financial Results
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics (NASDAQ:ABEO) Reports First Commercial Revenue and Bolstered Balance Sheet in 2025 ↗
Via Chartmill
News headline image
Earnings Scheduled For November 12, 2025 ↗
 
Via Benzinga
News headline image
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona (ABEO) Q4 2025 Earnings Call Transcript ↗
Abeona (ABEO) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Provides Business Update Highlighting Building Momentum in ZEVASKYN® Commercial Launch
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Keep an eye on the top gainers and losers in Wednesday's session. ↗
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Here's Why Abeona Therapeutics Popped Higher Today ↗
This company is making excellent progress on its treatment for a very rare and serious skin disorder. 
Via The Motley Fool
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
Let's have a look at the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Abeona Therapeutics (NASDAQ:ABEO) Stock Falls on Revenue Miss Despite Q3 EPS Beat ↗
Abeona Therapeutics beat Q3 EPS estimates but missed on revenue. The stock fell as investors focus on the delayed launch of its new gene therapy, ZEVASKYN. 
Via Chartmill
News headline image
Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
What to Expect from Abeona Therapeutics's Earnings ↗
 
Via Benzinga
News headline image
Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program
RDEA Pilot Program provides sponsors enhanced communication and collaboration with FDA to accelerate development of rare disease therapies 
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® and Children's Hospital Colorado Announce Newest Treatment Center for ZEVASKYN® Gene Therapy
From Abeona Therapeutics Inc.; Children's Hospital of Colorado
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >